Related Experiment Video
Updated: Jun 27, 2026

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
Fulminant myocarditis following coronavirus disease 2019 vaccination: a case report
Arianne Clare C Agdamag1, Daniel Gonzalez1, Katie Carlson2
1Division of Cardiology, Department of Medicine, University of Minnesota, 420 Delaware St., Minneapolis, MN 55455, USA.
Insights
Severe myocarditis is a rare complication following the BNT162b2 COVID-19 vaccine. This case highlights the importance of recognizing this adverse event, though vaccine benefits outweigh risks.
Area of Science:
- Cardiology
- Immunology
- Vaccinology
Background:
- The BNT162b2 vaccine (Pfizer-BioNTech) received emergency use authorization for preventing severe COVID-19.
- Myocarditis is a potential, albeit rare, adverse event associated with vaccination.
Observation:
- An 80-year-old female developed biopsy-proven fulminant myocarditis and cardiogenic shock within 12 days of her first BNT162b2 vaccine dose.
- The patient required mechanical circulatory support, inotropic agents, and high-dose steroids for management.
- Cardiac function recovered, with repeat MRI showing improved biventricular function and reduced myocardial inflammation after 3 months.
Findings:
- Fulminant myocarditis can occur as a rare complication post-BNT162b2 vaccination.
- Prompt medical intervention and management are crucial for patient recovery.
- Complete cardiac recovery is possible in severe cases of vaccine-associated myocarditis.
Implications:
- Clinicians must maintain vigilance for rare vaccine-related complications like myocarditis.
- Early recognition and management are key to improving outcomes.
- The established benefits of COVID-19 vaccination significantly outweigh the rare risks of adverse events.
Background:
The BNT162b2 vaccine received emergency use authorization from the U.S. Food and Drug Administration for the prevention of severe coronavirus disease 2019 (COVID-19) infection. We report a case of biopsy and magnetic resonance imaging (MRI)-proven severe myocarditis that developed in a previously healthy individual within days of receiving the first dose of the BNT162b2 COVID-19 vaccine.
Case Summary:
An 80-year-old female with no significant cardiac history presented with cardiogenic shock and biopsy-proven fulminant myocarditis within 12 days of receiving the BNT162b2 COVID-19 vaccine. She required temporary mechanical circulatory support, inotropic agents, and high-dose steroids for stabilization and management. Ultimately, her cardiac function recovered, and she was discharged in stable condition after 2 weeks of hospitalization. A repeat cardiac MRI 3 months after her initial presentation demonstrated stable biventricular function and continued improvement in myocardial inflammation.
Discussion:
Fulminant myocarditis is a rare complication of vaccination. Clinicians should stay vigilant to recognize this rare, but potentially deadly complication. Due to the high morbidity and mortality associated with COVID-19 infection, the clinical benefits of the BNT162b2 vaccine greatly outweighs the risks of complications.
More Related Videos
06:49Quantitative Visualization of Leukocyte Infiltrate in a Murine Model of Fulminant Myocarditis by Light Sheet Microscopy
Published on: May 31, 2017
06:38Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy
Published on: September 26, 2025
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Pericarditis I: Introduction